Advertisement
Singapore markets closed
  • Straits Times Index

    3,314.14
    +8.12 (+0.25%)
     
  • S&P 500

    5,464.62
    -8.55 (-0.16%)
     
  • Dow

    39,150.33
    +15.53 (+0.04%)
     
  • Nasdaq

    17,689.36
    -32.24 (-0.18%)
     
  • Bitcoin USD

    61,138.15
    -3,213.90 (-4.99%)
     
  • CMC Crypto 200

    1,262.42
    -47.30 (-3.61%)
     
  • FTSE 100

    8,277.42
    +39.70 (+0.48%)
     
  • Gold

    2,340.00
    +8.80 (+0.38%)
     
  • Crude Oil

    80.72
    -0.01 (-0.01%)
     
  • 10-Yr Bond

    4.2650
    +0.0080 (+0.19%)
     
  • Nikkei

    38,804.65
    +208.18 (+0.54%)
     
  • Hang Seng

    18,027.71
    -0.81 (-0.00%)
     
  • FTSE Bursa Malaysia

    1,589.66
    -0.71 (-0.04%)
     
  • Jakarta Composite Index

    6,889.17
    +9.19 (+0.13%)
     
  • PSE Index

    6,272.46
    +113.98 (+1.85%)
     

Kiniksa Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference

Kiniksa Pharmaceuticals, Ltd.
Kiniksa Pharmaceuticals, Ltd.

HAMILTON, Bermuda, June 04, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024 at 8:40 a.m. Eastern Time.

A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.

About Kiniksa
Kiniksa is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s immune-modulating assets, ARCALYST®, abiprubart, and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. For more information, please visit www.kiniksa.com.

ARCALYST® is a registered trademark of Regeneron Pharmaceuticals, Inc.

Every Second Counts! ®


Kiniksa Investor and Media Contact
Rachel Frank
(339) 970-9437
rfrank@kiniksa.com